Corcept Therapeutics' stock price surged about 228% from $35.69 on March 4 to $117.17 by August 18, significantly increasing the value of President Donald Trump's disclosed position in the company. The rally was driven by FDA backing for Corcept's drug relacorilant, positive clinical trial results showing a 35% reduction in death risk, and Trump's announcement of continued zero-percent tariffs on imported generic drugs until 2026. These factors helped Corcept's market cap reach $12.67 billion and pushed its shares higher amid favorable regulatory and trade developments.
XRP is increasingly vital on the XRP Ledger (XRPL), acting as the native bridge asset that facilitates efficient trade routing and liquidity. Over the past 72 hours, XRP was used in 0.16% of decentralized exchange (DEX) trades by automatically routin...
Bitcoin gained about 2.6%, reaching the $64,400-$64,500 range, while the S&P 500 dropped roughly 0.5% due to profit-taking in tech stocks. This marks a rare day where Bitcoin outperformed US equities, despite being down about 50% from its October 202...
WhiteHawk Minerals Corporation, a royalty-based mining company, reported a 57% year-over-year production increase in Q2 2026, supported by operator-funded drilling and disciplined acquisitions. The company maintains strong dividend coverage at 1.26 t...
Soluna Holdings is transitioning its business focus from Bitcoin mining to hosting AI data centers, with Q2 2026 revenue rising 145% to $15.06 million. Despite revenue growth, gross profit declined and the company's share count more than doubled due ...
Bitcoin surged 2.6% to over $64,000 on Monday, marking its best daily gain in over a month and outperforming the S&P 500, which fell 0.52%. This is notable as Bitcoin has underperformed the S&P 500 on about two-thirds of trading days in the past thre...
